English, , 236kb
This document reflects the OECD agreement on the list of economic activities (industries) for the information economy (ICT sector and Content and media sector definitions) based on the UN International Standard Industrial Classification of all Economic Activities (ISIC Rev. 4).
Companies can boost their stock market valuations and lower their cost of capital through improved reporting of intellectual assets and value creation strategies that overcome the limits of accounting standards, according to a report by the OECD.
English, , 2,675kb
This article shows the possible opportunities and risks of nanotechnologies today.
This document provides information on current/planned activities related to the safety of manufactured nanomaterials in OECD countries. Information was provided as written reports by delegations who participated in the 1st Meeting of OECD's Working Party on Manufactured Nanomaterials.
Further raising its high performance in innovation is of key importance for boosting Switzerland’s economic growth and maintaining high living standards. This review suggests some reforms in innovation policy which would help to cope with this challenge.
Proceedings of an international workshop to assess the causes behind the low participation of women in scientific careers, especially at senior levels, and to identify good practice policies to attract, recruit and retain women in scientific careers in public and private research.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.
Publications on Harmonisation of Regulatory Oversight in Biotechnology
English, , 436kb
This report documents the growing importance of intellectual assets for firms and the economy more generally and draws a number of implications for policy makers.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.